Micronized fenofibrate: Phase IV; marketed as adjunct to treat primary hypercholesterolemia

Researchers reported in The Lancet results from an international, placebo-controlled post-marketing study of micronized fenofibrate in 731 patients with Type II diabetes. Patients who received fenofib...